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Abstract
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically
heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and
mutations that result in aberrant cytokine receptor and kinase signaling. In particular, chro-
mosomal rearrangements resulting in the overexpression of cytokine receptor-like factor 2
(CRLF2) occur in 50% of Ph-like ALL cases. CRLF2 overexpression is associated with par-
ticularly poor clinical outcomes, though the molecular basis for this is currently unknown.
Glucocorticoids (GCs) are integral to the treatment of ALL and GC resistance at diagnosis is
an important negative prognostic factor. Given the importance of GCs in ALL therapy and
the poor outcomes for patients with CRLF2 overexpression, we hypothesized that the aber-
rant signal transduction associated with CRLF2 overexpression might mediate intrinsic GC
insensitivity. To test this hypothesis, we exposed Ph-like ALL cells from patient-derived
xenografts to GCs and found that CRLF2 rearranged (CRLF2R) leukemias uniformly dem-
onstrated reduced GC sensitivity in vitro. Furthermore, targeted inhibition of signal transduc-
tion with the MEK inhibitor trametinib and the Akt inhibitor MK2206, but not the JAK inhibitor
ruxolitinib, was sufficient to augment GC sensitivity. These data suggest that suboptimal GC
responses may in part underlie the poor clinical outcomes for patients with CRLF2 overex-
pression and provide rationale for combination therapy involving GCs and signal transduc-
tion inhibitors as a means of enhancing GC efficacy.
Introduction
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a subtype of
B-cell ALL that displays a gene expression profile resembling that of BCR-ABL1-positive ALL
but lacks the BCR-ABL1 translocation. Instead, Ph-like ALL is characterized by genetic alter-
ations that result in aberrant cytokine receptor and kinase signaling [1]. In particular, 50% of
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Ph-like ALL cases harbor chromosomal rearrangements that result in overexpression of cyto-
kine receptor-like factor 2 (CRLF2), which heterodimerizes with the interleukin-7 receptor
alpha chain to form the thymic stromal lymphopoietin receptor (TSLPR) [2]. Upon activation
by TSLP ligand, TSLPR signals through the JAK/STAT, Ras/MAPK, and PI3K/Akt/mTOR
pathways [3]. Importantly, overexpression of CRLF2 is associated with a particularly poor
prognosis, with these patients demonstrating significantly worse relapse-free survival relative
to patients without CRLF2 overexpression [2,4]. While the molecular basis for this clinical
observation is currently unknown, this suggests that these patients may have intrinsic resis-
tance to conventional chemotherapy.
Glucocorticoids (GCs) are an integral component of therapy for patients with ALL [5]. GCs
act by binding to a cytoplasmic GC receptor (GR), which promotes translocation of the GC/
GR complex to the nucleus and induction of a transcriptional program that results in apoptosis
in lymphoid cells [6]. Downstream effectors of signal transduction pathways have been shown
to inhibit several of these processes, including nuclear translocation of ligand-activated GR
[7,8] and induction of the GR transcriptional program [9]. Furthermore, cytokines present in
the microenvironment have been shown to promote GC resistance in lymphoblasts by activat-
ing these signal transduction pathways [10–12].
Given the importance of GC resistance in ALL and the comparatively poor clinical out-
comes for patients with CRLF2 overexpression, we hypothesized that the aberrant signal trans-
duction associated with CRLF2 overexpression might contribute to suboptimal responses to
GC therapy. We tested this hypothesis by assessing in vitro drug responses in CRLF2-rear-
ranged (CRLF2R) and -non-rearranged (CRLF2NR) cells from patient-derived xenografts of
Ph-like ALL, and found that CRLF2R samples were uniformly less sensitive to GCs relative to
many CRLF2NR samples. Furthermore, we demonstrated that GC sensitivity could be signifi-
cantly enhanced with concomitant signal transduction inhibition, providing rationale for fur-
ther evaluation of a combination therapy strategy as a means of augmenting GC sensitivity in
patients with CRLF2 overexpression.
Materials and methods
To assess GC sensitivity in Ph-like ALL cells, cryopreserved splenocytes were obtained from 19
patient-derived xenografts of high-risk Ph-like ALL established from treatment-naïve diagnos-
tic samples banked in the Children’s Hospital of Philadelphia leukemia biorepositories. Writ-
ten informed consent for the use of diagnostic specimens for future research was obtained
from patients or their guardians at the time of sample collection, according to the Declaration
of Helsinki and the National Cancer Institute and the institutional review board of Children’s
Hospital of Philadelphia, which approved this study. As a control to assess for in vitro drug tox-
icity, peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained from
Vitalant. Rearrangements involving the CRLF2 locus were detected as previously described
[2]. Cells were thawed, allowed to rest for 1 hour at 37˚C, then cultured at 37˚C in media sup-
plemented with 25 ng/mL recombinant human TSLP (Peprotech, Rocky Hill, NJ, USA). Ruxo-
litinib (Selleckchem, Houston, TX, USA), a JAK1/2 inhibitor, was used at 500nM while
dexamethasone (DEX; Sigma-Aldrich, St. Louis, MO, USA), a synthetic GC, trametinib (Sell-
eckchem), a MEK1/2 inhibitor, and MK2206 (Selleckchem), a pan-Akt inhibitor, were used at
1μM. Cells were harvested at 48 hours and flow cytometry was performed as previously
described using a FACSVerse flow cytometer (BD Biosciences, San Jose, CA, USA) [13]. Anti-
sera included anti-human CD45, anti-cleaved caspase-3, anti-TSLPR, anti-STAT5 (pY694),
anti-ERK1/2 (pT202/pY204), anti-Akt (pS473) (BD Biosciences), and anti-GR (Cell Signaling,
Danvers, MA, USA). Signal strength was quantified as the median fluorescence intensity
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(MFI) of cells negative for cleaved caspase-3 within the human CD45-positive gate. Viability
assays were performed via calculation of the frequency of Hoechst (ThermoFisher, Waltham,
MA, USA) negative cells in the human CD45-positive gate. All viability data are presented as
the percentage of viable cells in the drug-treated condition relative to the percentage of viable
cells in the corresponding vehicle control condition for each individual sample. The average
viability across all samples in the vehicle control condition at 48 hours was 39% +/- 23%. Statis-
tical analyses were performed using Prism 8 (GraphPad, San Diego, CA, USA). All tests were
two-sided and the threshold for significance was p�0.05. Specifically, comparisons between
groups were made using t-tests, with one-way ANOVA and Tukey’s method for multiple com-
parisons adjustment used for comparisons of three or more groups. Drug-drug interactions
were assessed using the Bliss independence model of synergy [14]
Results
Eleven of the 19 Ph-like leukemias were positive for CRLF2 rearrangements. Of these, nine
expressed transcripts corresponding to the IGH@-CRLF2 rearrangement and two were posi-
tive for the P2RY8-CRLF2 rearrangement. Seven of these CRLF2R leukemias had concomitant
activating mutations in JAK2. All eight CRLF2NR Ph-like leukemias had point mutations or
rearrangements involving other kinases previously implicated in Ph-like ALL [15] (S1 Table).
Both IGH@-CRLF2 and P2RY8-CRLF2 translocations have been reported to result in
CRLF2 overexpression [16]. Consistent with these data, the CRLF2R leukemias analyzed in the
current study exhibited higher cell surface TSLPR protein expression relative to CRLF2NR leu-
kemias (p = 0.0003; Fig 1A). We next assessed the induction of phosphorylated (p) STAT5,
ERK, and Akt in response to short-term TSLP stimulation in CRLF2R and CRLF2NR leukemias.
Four of 10 CRLF2R leukemias, including two that lacked a concomitant JAK2 mutation,
markedly induced pSTAT5 in response to short-term TSLP stimulation, while CRLF2NR leuke-
mias did not (Fig 1B). CRLF2R leukemias also induced pERK and pAkt in response to TSLP,
with no induction in the CRLF2NR leukemias (p = 0.001 and p = 0.002 versus CRLF2NR leuke-
mias, respectively; Fig 1C and 1D). There were no differences in basal levels of pSTAT5,
pERK, or pAkt between CRLF2R and CRLF2NR leukemias (S1 Fig).
Fig 1. CRLF2R leukemias demonstrate TSLPR overexpression and increased signal transduction activity relative to CRLF2NR leukemias. (A) MFI of TSLPR cell
surface protein expression as determined by antibody staining and flow cytometry in cells from CRLF2R and CRLF2NR samples. Individual patient samples are shown in
the same color in all figures and in S1 Table. (B-D) Induction of (B) pSTAT5, (C) pERK, and (D) pAkt in CRLF2R and CRLF2NR samples in response to a 30-minute
stimulation with 25ng/mL TSLP, presented as the fold change in MFI following TSLP stimulation relative to the basal condition. Samples JH721 and NL432 were not
included in this analysis due to limitations in cell number. Error bars represent the standard error of the mean. Statistical significance was assessed using a two-sample t-
test. ����p<0.0001, ���p<0.001, ��p<0.01, �p<0.05.
https://doi.org/10.1371/journal.pone.0220026.g001
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To test the hypothesis that aberrant signal transduction might impair GC sensitivity in
CRLF2R leukemias, we assessed the response to DEX in vitro. In the presence of DEX, all 11
CRLF2R leukemias retained greater than 50% survival at 48 hours, in contrast to only four
CRLF2NR leukemias (p = 0.006 versus CRLF2NR leukemias; Fig 2A). Importantly, this differ-
ence in DEX sensitivity was not explained by differences in GR expression (S2A Fig). Given
the uniform DEX insensitivity in the CRLF2R leukemias, we asked whether inhibition of one
or more signal transduction pathways downstream of TSLPR might augment DEX-induced
cell death in these samples. We treated these leukemias with the combination of DEX and
inhibitors of JAK1/2 (ruxolitinib), MEK (trametinib), or Akt (MK2206) at concentrations that
attenuated TSLP-induced signaling in the CRLF2R Ph-like ALL cell line Mutz-5 (S2B–S2D Fig)
and that did not demonstrate toxicity in healthy PBMCs (S2E Fig). In the CRLF2R samples,
ruxolitinib had no significant single agent effect when assessed across the entire cohort, but it
showed increased efficacy in samples with a JAK2 mutation relative to those without (p = 0.03;
S3A Fig). Furthermore, the combination of DEX and ruxolitinib was not more effective than
either agent alone (Fig 2B). In contrast, trametinib and MK2206, which showed moderate sin-
gle-agent activity (p = 0.005 and p = 0.04 versus vehicle, respectively), were significantly more
effective in combination with DEX relative to either single agent alone (p = 0.005 and
p<0.0001 versus DEX alone, respectively; Fig 2C and 2D). Bliss independence analysis con-
firmed these findings, demonstrating no interaction between DEX and RUX but cooperativity
between DEX and trametinib and DEX and MK2206 (Fig 2E–2G). In the CRLF2NR samples,
Fig 2. CRLF2R leukemias are uniformly DEX resistant and can be sensitized to DEX with targeted inhibition of MEK or Akt. (A) Cell viability in response to 1μM
DEX, presented as the percentage of viable cells in the DEX treated condition relative to the vehicle control condition in CRLF2R and CRLF2NR samples. (B-D) Cell
viability of CRLF2R samples following exposure to 1μM DEX, (B) 500nM ruxolitinib, (C) 1μM trametinib, (D) 1μM MK2206, or a combination of DEX and a targeted
inhibitor presented as the percentage of viable cells in the drug treated conditions relative to the vehicle control condition. (E-G) Bliss independence scores for the
combination of DEX and ruxolitinib (E), trametinib (F), or MK2206 (G) in CRLF2R samples, in which positive values indicate a synergistic interaction between the two
agents. Error bars represent the standard error of the mean. Statistical significance was assessed using a two-sample t-test (A) or one-way ANOVA with Tukey’s method
for multiple comparisons adjustment (B-D). ����p<0.0001, ���p<0.001, ��p<0.01, �p<0.05.
https://doi.org/10.1371/journal.pone.0220026.g002
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these signal transduction inhibitors demonstrated variable effects, with some modulation of
DEX sensitivity in several samples that demonstrated relative insensitivity to DEX as a single
agent (S3B–S3D Fig).
Discussion
Taken together, these data demonstrate that Ph-like ALL samples with CRLF2 rearrangements
uniformly demonstrate limited GC sensitivity in vitro. Furthermore, these data suggest a
model whereby dysregulated signal transduction in the context of CRLF2 overexpression con-
tributes to relative GC resistance. This provides rationale for a clinical strategy involving com-
bination therapy with GCs and signal transduction inhibitors as a means of enhancing GC
efficacy. A precedent for this type of combination therapy approach includes the addition of
ABL kinase inhibitors to standard chemotherapy regimens for children with Ph-positive ALL,
which has dramatically improved clinical outcomes for these patients [17]. Together with the
known prognostic value of GC sensitivity, our findings suggest that the inferior survival rates
for patients with CRLF2 overexpression may be driven at least in part by suboptimal responses
to GC therapy. These data support further evaluation of CRLF2 rearrangement status as a clini-
cal biomarker for relatively poor sensitivity to GCs, thereby enabling the identification of
patients who may benefit from the addition of molecularly targeted therapy to conventional
anti-leukemia chemotherapy.
Supporting information
S1 Fig. MFI of basal (A) pSTAT5, (B) pERK, and (C) pAkt in CRLF2R and CRLF2NR leuke-
mias. Error bars represent the standard error of the mean. Statistical significance was assessed
using a two-sample t-test.
(TIF)
S2 Fig. (A) MFI of intracellular GR protein expression as determined by flow cytometry in
CRLF2R and CRLF2NR samples. (B-D) Histograms indicating levels of (B) pSTAT5, (C)
pERK, or (D) pAkt following TSLP stimulation with or without one hour pre-treatment with
500nM ruxolitinib, 1μM trametinib, or 1μM MK2206, respectively, in the CRLF2R Ph-like
ALL cell line Mutz-5. (E) Viability of PBMCs from three healthy donors following exposure to
500nM ruxolitinib, 1μM trametinib, or 1μM MK2206. Error bars represent the standard error
of the mean. Statistical significance was assessed using a two-sample t-test (A) or one-way
ANOVA with Tukey’s method for multiple comparisons adjustment (E).
(TIF)
S3 Fig. (A) Cell viability of CRLF2R samples with JAK2 mutations versus those without JAK2
mutations following exposure to 500nM ruxolitinib. (B-D) Cell viability of CRLF2NR samples
following exposure to 1μM DEX, (B) 500nM ruxolitinib, (C) 1μM trametinib, (D) 1μM
MK2206, or a combination of DEX and a targeted inhibitor presented as the percentage of via-
ble cells in the drug treated conditions relative to the vehicle control condition. Error bars rep-
resent the standard error of the mean. Statistical significance was assessed using a paired t-test
(A) or one-way ANOVA with Tukey’s method for multiple comparisons adjustment (B-D).
����p<0.0001, ���p<0.001, ��p<0.01, �p<0.05.
(TIF)
S1 Table. Characteristics of Ph-like ALL samples.
(TIF)
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